Synthetic thiazolidinediones (TZDs) and PPAR-γ agonists, including rosiglitazone and pioglitazone, could effectively improve insulin sensitivity and lower the blood glucose level in patients with Type 2 diabetes [53]. The gene discussed is INS; the disease is type 2 diabetes mellitus.